非肝硬化门静脉系统血栓形成临床管理

doi:10.3969/j.issn.1672-5069.2024.01.003

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (1): 7-10.doi: 10.3969/j.issn.1672-5069.2024.01.003

非肝硬化门静脉系统血栓形成临床管理

鲁文婷, 张峰

210008 南京市南京大学医学院附属鼓楼医院消化内科

收稿日期:2023-10-26 出版日期:2024-01-10 发布日期:2024-01-04
通讯作者: 张峰,E-mail:fzdndx@126.com
作者简介:鲁文婷,女,25岁,硕士研究生。E-mail:luwenting9858@outlook.com

Clinical management of patients with non-cirrhotic portal veinthrombosis

Lu Wenting, Zhang Feng

Department of Gastroenterology, DrumTower Hospital, Affiliated to Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China

Received:2023-10-26 Online:2024-01-10 Published:2024-01-04

摘要/Abstract

关键词: 非肝硬化门静脉系统血栓形成, 病因, 诊断, 治疗

Key words: Non-cirrhosis portal venous thrombosis, Etiology, Diagnosis, Treatment

鲁文婷, 张峰. 非肝硬化门静脉系统血栓形成临床管理[J]. 实用肝脏病杂志, 2024, 27(1): 7-10.

Lu Wenting, Zhang Feng. Clinical management of patients with non-cirrhotic portal veinthrombosis[J]. Journal of Practical Hepatology, 2024, 27(1): 7-10.

[1] Rajani R, Bjornsson E, Bergquist A, et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther, 2010,32(9):1154-1162.
[2] Hernández-Gea V, De Gottardi A, Leebeek FWG, et al. Current knowledge in patho-physiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral s-planchnic vein thrombosis. J Hepatol, 2019,71(1):175-199.
[3] Garcia-Pagán JC, Hernández-Guerra M, Bosch J. Extrahepatic portal vein thrombosis.Semin Liver Dis, 2008,28(03):282-292.
[4] Spaander VM, van Buuren HR, Janssen HL. The management of non-cirrhotic non-malignant portal vein thrombosis and concurrent portal hypertension in adults. Aliment Pharmacol Ther, 2007,26(s2):203-209.
[5] Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost, 2018,16(2):231-241.
[6] Falanga A, Russo L, Milesi V, et al. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol, 2017,118:79-83.
[7] Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res, 2014,133:S149-S157.
[8] Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022,140(11):1200-1228.
[9] Elkrief L, Payancé A, Plessier A, et al. Management of splanchnic vein thrombosis. JHEP Rep, 2023,5(4):100667.
[10] Kiladjian JJ, Cassinat B. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. Am J Hematol, 2023,98(5):794-800.
[11] Moliterno AR, Kaizer H. Applied genomics in MPN presentation. Hematology Am Soc Hematol Educ Program, 2020,2020(1):434-439.
[12] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol, 2022,76(4):959-974.
[13] Bureau C, Laurent J, Robic MA, et al. Central obesity is associated with non-cirrhotic portal vein thrombosis. J Hepatol, 2016,64(2):427-432.
[14] Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 2007,56(4):1010-1013.
[15] Mamad H, Benkirane S, El Aissaoui Y, et al. Prothrombotic disorders in non-cirrhotic, non-tumoral portal vein thrombosis. Thromb Res, 2021,203:152-154.
[16] De Broucker C, Plessier A, Ollivier-Hourmand I, et al. Multicenter study on recent p-ortal venous system thrombosis associated with cytomegalovirus disease. J Hepatol, 2022,76(1):115-122.
[17] Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombo-sis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology, 2010,51(1):210-218.
[18] Llop E, Seijo S. Actuación ante la trombosis portal no cirrótica no tumoral. Gastroenterol Hepatol, 2016,39(6):403-410.
[19] Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology, 2016,63(5):1640-1650.
[20] Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021,73(1):366-413.
[21] Bettiol A, Alibaz-Oner F, Direskeneli H, et al. Vascular Behçet syndrome: from pathogenesis to treatment. Nat Rev Rheumatol, 2023,19(2):111-126.
[22] Sicre de Fontbrune F, Peffault de Latour R. Ten years of clinical experience with eculizumab in patients with paroxysmal mocturnal hemoglobinuria. Semin Hematol, 2018,55(3):124-129.
[23] Baiges A, Procopet B, Silva-Junior G, et al. Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis. J Hepatol, 2023,78(1):114-122.
[24] Naymagon L, Tremblay D, Schiano T, et al. The role of anticoagulation in pylephle-bitis: a retrospective examination of characteristics and outcomes. J Thromb Thrombo-lysis, 2020,49(2):325-331.
[25] Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management o-f the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis, 2016,41(1):206-232.
[26] Naymagon L, Tremblay D, Zubizarreta N, et al. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv, 2020,4(4):655-666.
[27] Mansour N, Öcal O, Gerwing M, et al. Interventional recanalization therapy in patients with non-cirrhotic, non-malignant portal vein thrombosis: comparison between transjugular versus transhepatic access. Abdom Radiol (NY), 2022,47(3):1177-1186.

非肝硬化门静脉系统血栓形成临床管理

Clinical management of patients with non-cirrhotic portal veinthrombosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	诸葛宇征. 重视内脏静脉血栓形成的诊断和管理^*[J]. 实用肝脏病杂志, 2024, 27(1): 1-2.
[2]	靳珂珂, 丁惠国. 肝硬化门静脉血栓形成风险监测及抗凝管理^*[J]. 实用肝脏病杂志, 2024, 27(1): 3-6.
[3]	张明. 肝硬化门静脉血栓形成诊治新进展[J]. 实用肝脏病杂志, 2024, 27(1): 11-15.
[4]	李凯, 石波, 程序, 赵凯. 应用STE/STQ技术评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 20-23.
[5]	唐智权, 杨婷, 李开铃. 索磷布韦/达拉他韦治疗的慢性丙型肝炎患者血尿酸水平变化研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 28-31.
[6]	王焱, 韩军, 杨美蓉. 三种DAAs方案治疗慢性丙型肝炎患者两年随访研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 32-35.
[7]	黄洁杰, 郑倩, 吕睿, 王瑞萍. 利拉鲁肽联合阿托伐他汀钙治疗伴有糖脂代谢异常的非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 36-39.
[8]	叶茜, 郑东, 杨昕宇, 郭江, 符美茵, 谢燕华, 刘洪. 超声衰减参数联合血清PAI-1和ALT水平评估代谢相关脂肪性肝病患者肝脂肪变性程度的价值分析^*[J]. 实用肝脏病杂志, 2024, 27(1): 44-47.
[9]	张书琴, 王婷婷, 张艳红. 实时组织弹性成像评估非酒精性脂肪性肝炎患者肝纤维化分期临床价值研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 48-51.
[10]	闫玉婷, 贾桂, 孟琴, 高欣欣. 自身免疫性肝炎和原发性胆汁性胆管炎患者甲状腺功能变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2024, 27(1): 52-55.
[11]	杨晶, 陈美玲, 张丽秀, 颜鲁伟, 白正强, 贺锐. 慢加急性乙型肝炎肝衰竭患者细菌感染病原菌分布及血清PCT、IFN-γ和IL-6水平变化分析^*[J]. 实用肝脏病杂志, 2024, 27(1): 64-67.
[12]	穆玉娟, 吴斐斐, 陈莹. 磁共振增强T1 mapping和IVIM-DWI技术评估乙型肝炎肝硬化患者肝脏储备功能价值研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 68-71.
[13]	宋一凡, 郑帅, 许芸, 唐铁骑. 超声半定量评分结合瞬时弹性成像技术评估乙型肝炎肝硬化并发食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 72-75.
[14]	李新力, 秦长江, 尹方方. 特利加压素治疗肝硬化并发食管胃静脉曲张破裂出血患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 76-79.
[15]	郝永欣, 孟祥安, 骆允, 高美丽, 刘欢, 刘磊, 沈荣. 超声造影与增强CT检查诊断小肝癌效能比较^*[J]. 实用肝脏病杂志, 2024, 27(1): 88-91.